Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051130 | 0.86 | USP2 (0.42) | TGFBR1USP2PLA2G2CMEN1KMT2A | |
| SCHEMBL6025190 | 0.75 | USP2 (0.48) | USP2 | |
| SCHEMBL16746550 | 0.75 | MMP9 (0.45) | — | |
| SCHEMBL23049027 | 0.73 | THRB (0.38) | TGFBR1MEN1KMT2A | |
| SCHEMBL10453102 | 0.73 | USP2 (0.44) | USP2MEN1KMT2A | |
| SCHEMBL16134391 | 0.72 | USP2 (0.42) | USP2MEN1KMT2A | |
| SCHEMBL10051131 | 0.72 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL15935691 | 0.72 | USP2 (0.46) | USP2PLA2G2CMEN1KMT2A | |
| SCHEMBL24462897 | 0.72 | USP2 (0.46) | USP2PLA2G2CMEN1KMT2A | |
| SCHEMBL867377 | 0.72 | TSHR (0.46) | TGFBR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987410-B2 | Terminal unsaturated, glycidol-based macromonomers, polymers obtainable therefrom, preparation and use | BYK-CHEMIE GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987410-B2 | Terminal unsaturated, glycidol-based macromonomers, polymers obtainable therefrom, preparation and use | BYK-CHEMIE GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2443170-B1 | TERMINAL UNSATURATED, GLYCIDOL BASED MACROMONOMERS, POLYMERS OBTAINABLE THEREFROM, PRODUCTION AND USE THEREOF | BYK CHEMIE GMBH (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-20120165414-A1 | TERMINAL UNSATURATED, GLYCIDOL-BASED MACROMONOMERS, POLYMERS OBTAINABLE THEREFROM, PREPARATION AND USE | BYK-CHEMIE GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165414-A1 | TERMINAL UNSATURATED, GLYCIDOL-BASED MACROMONOMERS, POLYMERS OBTAINABLE THEREFROM, PREPARATION AND USE | BYK-CHEMIE GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2010145761-A1 | TERMINAL UNSATURATED, GLYCIDOL BASED MACROMONOMERS, POLYMERS OBTAINABLE THEREFROM, PRODUCTION AND USE THEREOF | BYK-CHEMIE GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
| EP-2264082-A1 | Terminal unsaturated glycidol-based marcomonomers, polymers obtained from them, manufacture and use | BYK-Chemie GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165414-A1 | TERMINAL UNSATURATED, GLYCIDOL-BASED MACROMONOMERS, POLYMERS OBTAINABLE THEREFROM, PREPARATION AND USE | OXER1, OXGR1, ACSL3 | TGFBR1 1915/4885USP2 2076/4885PLA2G2C 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.